Last updated Nov 17, 2026. 55 unique records for ipamorelin. 2026 is a partial year. Ten of the 2026 records are broader sports-peptide or survey papers that mention ipamorelin among other agents. Cards on this page use compound-specific papers, not those surveys. Source on PubMed
RC-IPA · Endocrine Signaling Research
RC-IPA
Endocrine Signaling Research
Vial sizes for laboratory supply, not a protocol.
Key specifications
Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.
- Catalog title
- RC-IPA | Endocrine Signaling Research
- Research focus
- Endocrine Signaling Research
- Also described as
- Ipamorelin
- Format
- Lyophilized research peptide
- Catalog status
- In stock (public listing)
- Presentations
- 5 mg vialCatalog sizes, not a protocol
- Molecular formula
- C38H49N9O5PubChem CID 9831659
- Molecular weight
- 711.9PubChem average; exact mass 711.38566570
- Receptor context
- Described in the literature as a selective ghrelin receptor (GHS-R1a) agonistLiterature description; research context only
- Sequence
- Not reproduced hereSee primary literature / PubChem
- Researcher access
- Sign-in required to view pricing
- PubMed records
- 55 uniqueQuery above, Nov 17, 2026
Catalog notes & use limitations
Research-catalog framing only. This section does not describe effects in people or study outcomes.
Catalog notes
Listed under Endocrine Signaling Research
RC-IPA appears in the PEPTIDEA™ Endocrine & Growth Factor Signaling Research collection with other endocrine-focus materials, including RC-TESA, RC-CJCIPA, and RC-KSP.
Distinct from the CJC/ipamorelin blend
RC-CJCIPA is catalogued separately as a multi-constituent product. This page is the single-compound ipamorelin listing.
5 mg vial
The catalog presentation is a 5 mg vial. That is a presentation of the research material, not a protocol.
Use limitations
Research use only
Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.
No outcome or dosing information
This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.
Confirm details from primary sources
Formula and molecular weight are cited from PubChem when a single compound applies; otherwise see the catalog notes. Sequence is omitted. Read the original papers for laboratory context — results stay in the original publications.
Specifications
Laboratory-catalog and public-chemistry details. Items without a cited source are marked.
| Catalog title | RC-IPA | Endocrine Signaling Research |
|---|---|
| Category | Endocrine Signaling Research (Endocrine & Growth Factor Signaling Research) |
| Associated names | Ipamorelin |
| Format | Lyophilized research peptide |
| Public catalog status | In stock (as of Nov 17, 2026) |
| Catalog presentations | 5 mg vial — sizes of the research material, not a use protocol |
| Molecular formula | C38H49N9O5 (PubChem CID 9831659, retrieved Nov 17, 2026) |
| Molecular weight | 711.9 (PubChem average; exact mass 711.38566570) |
| InChIKey | NEHWBYHLYZGBNO-BVEPWEIPSA-N (PubChem) |
| Receptor context | Published papers describe ipamorelin as a synthetic pentapeptide growth-hormone secretagogue and selective agonist of the ghrelin receptor (GHS-R1a). That is a mechanism-class description, not a use claim. |
| Sequence | Not reproduced on this page. See primary literature and the PubChem record. |
| Pricing | Visible after researcher sign-in |
Research literature
These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.
Raun et al.
This paper introduces ipamorelin as a synthetic pentapeptide growth-hormone secretagogue and reports in-vitro and in-vivo pharmacology, including comparisons with earlier secretagogues.
Potency, selectivity, and other experimental results in the paper are not restated on this page.
Gobburu et al.
This paper reports pharmacokinetic and pharmacodynamic modeling of ipamorelin in healthy volunteers.
Infusion rates, pharmacokinetic parameters, and growth-hormone response values in the paper are not reproduced here.
Ankersen et al.
This paper describes a medicinal-chemistry series of growth-hormone-releasing peptides derived from ipamorelin, including peptidomimetic modifications.
Structure–activity findings and any bioavailability discussion in the paper are not restated here.
Greenwood-Van Meerveld et al.
This paper studied ipamorelin, described as a ghrelin-receptor agonist, in a rodent model of postoperative gastric dysmotility.
Transit measurements and any other experimental results in the paper are not reproduced on this page.
Venkova et al.
This paper examined ipamorelin, described as a selective growth-hormone secretagogue and ghrelin-receptor agonist, in a rodent model of postoperative ileus, with measurements of gastrointestinal transit.
Transit findings and any other experimental results in the paper are not restated here.
Beck, Sweeney, and McCarter
This prospective, randomized, controlled, proof-of-concept phase 2 study evaluated ipamorelin in adults after bowel resection, in a postoperative gastrointestinal-motility research setting.
Endpoints, administration schedules, and any results reported in the paper are not reproduced on this page.
Original titles are omitted or neutralized when they use clinical-outcome wording. Counts and the optional source links use the query ipamorelin. Source on PubMed
Storage & handling
General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.
- Handle as a lyophilized research material intended for laboratory use only.
- Store according to the conditions printed on the label and in any compound document provided to approved researchers.
- Protect closed vials from moisture and unnecessary temperature swings.
- If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
- This material is not for human or veterinary use and is not medical advice.
Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.




